Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.
malignant pleural mesothelioma
multidisciplinary
pleurectomy
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
10
08
2022
received:
22
06
2022
accepted:
11
08
2022
pubmed:
3
9
2022
medline:
5
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence of treatments within the trimodality is unclear, and should be decided upon a multidisciplinary consensus for each individual patient. Here, we analyzed the perioperative data of 19 MPM patients who underwent extended pleurectomy/decortication (EPD) with curative intent. The mean age at diagnosis was 67 years; 11 males and eight females. Ten patients were diagnosed with MPM via medical thoracoscopy (MT), and nine via video-assisted thoracoscopic surgery (VATS). The vast majority of cases harbored epitheliod forms. We compared neoadjuvant chemotherapy (NCT) followed by surgery (11 cases) versus surgery followed by adjuvant chemotherapy (ACT, 8 cases) within a 3-year period. All patients had extended pleurectomy/decortication and none had an extended pneumonectomy. Analysis of survival curves suggested that the short-term outcomes are better with upfront EDP followed by ACT if compared to EDP preceded by NCT. Although limited, the data highlighted the safety and feasibility of EPD, with manageable postoperative complications and no major burden for the patients.
Identifiants
pubmed: 36052736
doi: 10.1111/1759-7714.14627
pmc: PMC9527178
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2792-2798Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Trials. 2019 Oct 18;20(1):598
pubmed: 31627746
Transl Lung Cancer Res. 2018 Oct;7(5):556-561
pubmed: 30450294
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S100-S119
pubmed: 32206576
BMC Cancer. 2021 Jul 1;21(1):762
pubmed: 34210265
Int J Nanomedicine. 2019 Jan 23;14:773-785
pubmed: 30774332
Cureus. 2019 Feb 20;11(2):e4102
pubmed: 31057996
Cancer Immunol Immunother. 2011 Nov;60(11):1509-27
pubmed: 21913025
Thorac Cancer. 2022 Oct;13(19):2792-2798
pubmed: 36052736
Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5
pubmed: 27224058
Transl Lung Cancer Res. 2017 Apr;6(2):212-219
pubmed: 28529903
Acta Biomed. 2017 Aug 23;88(2):134-142
pubmed: 28845826
Int J Mol Sci. 2021 Aug 20;22(16):
pubmed: 34445720
J Thorac Dis. 2015 Dec;7(Suppl 4):S339-51
pubmed: 26807282
Cancers (Basel). 2020 May 07;12(5):
pubmed: 32392897
Clin Transl Radiat Oncol. 2021 Jan 01;27:85-88
pubmed: 33532635
Radiographics. 2004 Jan-Feb;24(1):105-19
pubmed: 14730040
Transl Lung Cancer Res. 2017 Jun;6(3):285-294
pubmed: 28713674
J Thorac Dis. 2018 Jan;10(Suppl 2):S293-S297
pubmed: 29507798
Lung Cancer. 2014 Feb;83(2):240-5
pubmed: 24360321
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008306
Cell Adh Migr. 2010 Jan-Mar;4(1):153-61
pubmed: 20179421
Ann Oncol. 2022 Feb;33(2):129-142
pubmed: 34861373
Front Oncol. 2022 May 02;12:886430
pubmed: 35586499